netFormulary
 Report : A-Z CDF items in Formulary 22/10/2020 16:03:07
[Back]
 
Section Status CDF Name
08.02.04 Formulary Cancer Drugs Fund Atezolizumab  (Tecentriq®)
08.02.04 Formulary Cancer Drugs Fund Avelumab  (Bavencio®)
08.02.04 Formulary Cancer Drugs Fund Axicabtagene ciloleuce (Yescarta®)
08.01.01 Formulary Cancer Drugs Fund Bendamustine 
08.01.05 Formulary Cancer Drugs Fund Bevacizumab Avastin®
08.02 Formulary Cancer Drugs Fund Blinatumomab Blincyto®
08.01.05 Formulary Cancer Drugs Fund Bortezomib Velcade®
08.01.05 Formulary Cancer Drugs Fund Bosutinib Bosulif®
08.01.05 Formulary Cancer Drugs Fund Brentuximab vedotin Adcetris®
08.01.05 Formulary Cancer Drugs Fund Cabozantinib Cabometyx®
08.01 Formulary Cancer Drugs Fund Cemiplimab Libtayo®
08.01.05 Formulary Cancer Drugs Fund Cetuximab Erbitux®
08.01.03 Formulary Cancer Drugs Fund Clofarabine Evoltra®
08.01.05 Formulary Cancer Drugs Fund Crizotinib Xalkori®
08.01.05 Formulary Cancer Drugs Fund Dabrafenib Tafinlar®
08.01.05 Formulary Cancer Drugs Fund Dacomitinib Vizimpro®)
08.02.04 Formulary Cancer Drugs Fund Daratumumab  (Darzalex®)
08.01.05 Restricted Use Cancer Drugs Fund Dasatinib Sprycel®
08.02.04 Formulary Cancer Drugs Fund Dinutuximab  (Qarziba®)
08.01.02 Formulary Cancer Drugs Fund Doxorubicin Caelyx®
08.02.04 Formulary Cancer Drugs Fund Durvalumab   (Imfinzi® )
08.01.05 Formulary Cancer Drugs Fund Eribulin Halaven®
08.01.05 Restricted Use Cancer Drugs Fund Everolimus Afinitor®
08.02.04 Formulary Cancer Drugs Fund Glatiramer Acetate Copaxone®
08.01.05 Formulary Cancer Drugs Fund Ibrutinib Imbruvica®
08.02.04 Formulary Cancer Drugs Fund Immunocellular therapy containing tisagenlecleucel, autologous T cells genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor (CAR) (Kymriah®)
08.01 Formulary Cancer Drugs Fund Inotuzumab ozogamicin Besponsa®
08.01.05 Formulary Cancer Drugs Fund Ipilimumab Yervoy®
08.01.05 Formulary Cancer Drugs Fund Ixazomib Ninlaro®
08.02.04 Formulary Cancer Drugs Fund Lenalidomide 
08.01.03 Formulary Cancer Drugs Fund Nelarabine Atriance®
08.01.05 Formulary Cancer Drugs Fund Neratinib 
08.02.04 Formulary Cancer Drugs Fund Niraparib (Zejula®)
08.02.04 Formulary Cancer Drugs Fund Nivolumab Opdivo®
08.02.04 Formulary Cancer Drugs Fund Osimertinib Tagrisso
08.01.05 Formulary Cancer Drugs Fund Panitumumab Vectibix®
08.01.05 Formulary Cancer Drugs Fund Pembrolizumab Keytruda®
08.01.03 Formulary Cancer Drugs Fund Pemetrexed Alimta®
08.02.04 Formulary Cancer Drugs Fund Pemrolizumab Keytruda®
08.01.05 Formulary Cancer Drugs Fund Pertuzumab Perjeta®
08.02.04 Formulary Cancer Drugs Fund Pomalidomide Imnovid®
08.01.05 Formulary Cancer Drugs Fund Ponatinib Iclusig®
08.03.04.02 Formulary Cancer Drugs Fund Radium-223 dichloride 
08.01.05 Formulary Cancer Drugs Fund Regorafenib Stivarga®
08.01.05 Formulary Cancer Drugs Fund Ribociclib 
08.01.05 Formulary Cancer Drugs Fund Rucaparib 
08.01.05 Formulary Cancer Drugs Fund Sorafenib Nexavar®
08.01.05 Formulary Cancer Drugs Fund Sunitinib Sutent®
08.02.04 Formulary Cancer Drugs Fund Talimogene laherparepvac Imlygic®
08.01.05 Formulary Cancer Drugs Fund Temsirolimus Torisel®
08.02.04 Formulary Cancer Drugs Fund Teriflunomide Aubagio®
08.01.05 Formulary Cancer Drugs Fund Trametinib Mekinist®
08.01.05 Formulary Cancer Drugs Fund Trastuzumab emtansine Kadcyla®
08.01.05 Formulary Cancer Drugs Fund Trifluridine and Tipiracil  Lonsurf ®
08.01.05 Formulary Cancer Drugs Fund Venetoclax Venclyxto ®
Northern Lincolnshire